[go: up one dir, main page]

WO2005094365A2 - Polypeptides et polynucleotides ten-m3, et procedes d'utilisation correspondants - Google Patents

Polypeptides et polynucleotides ten-m3, et procedes d'utilisation correspondants Download PDF

Info

Publication number
WO2005094365A2
WO2005094365A2 PCT/US2005/010680 US2005010680W WO2005094365A2 WO 2005094365 A2 WO2005094365 A2 WO 2005094365A2 US 2005010680 W US2005010680 W US 2005010680W WO 2005094365 A2 WO2005094365 A2 WO 2005094365A2
Authority
WO
WIPO (PCT)
Prior art keywords
cell
cells
protein
seq
antibody
Prior art date
Application number
PCT/US2005/010680
Other languages
English (en)
Other versions
WO2005094365A3 (fr
Inventor
Ramesh Kekuda
Timothy K. Maclachlan
Meera Patturajan
Luca Rastelli
Corine Vernet
Seth Ettenberg
Original Assignee
Curagen Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curagen Corporation filed Critical Curagen Corporation
Publication of WO2005094365A2 publication Critical patent/WO2005094365A2/fr
Publication of WO2005094365A3 publication Critical patent/WO2005094365A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Definitions

  • the present invention relates to compositions and methods for preventing and treating cancer. More particularly, the present invention relates to compositions comprising Ten-M3, CG55069, a fragment, a derivative, a variant, a homolog, or an analog thereof, and antibodies thereto and their uses in preventing and treating cancer.
  • Ten-M family of genes also known as teneurins or hOdz, are a class of type II membrane proteins containing a short intracellular N-terminus, a transmembrane region followed extracellularly by 8 epidermal growth factor (EGF)-like repeats and a large globular domain.
  • EGF epidermal growth factor
  • the EGF repeats found in Ten-M proteins are thought to mediate dimerization which may regulate their function.
  • Drosophila Ten-m protein was originally discovered as the first pair- rule gene that was not a transcription factor.
  • the expression patterns of mouse and chicken homologues of Ten-M proteins suggest a role in neuronal development and neurite outgrowth.
  • the murine family of Ten-m protein homologs consists of at least four members (Ten-m1 -4) each possessing similar structural features.Ten-M proteins may bind extracellular matrix proteins such as heparin, indicating a role as a cell adhesion molecule. mRNA levels of human Ten-M proteins, appear to be upregulated in certain cancers, and may be implicated in metastatic cell migration. [Dev. Biol. 216, 195-209 (1999), J. Cell Biol. 145, 563-577 (1999)].
  • compositions comprising CG55069 polypeptide or polynucleotide and antibodies to CG55069 polypeptides.
  • the invention provides methods of preventing angiogenesis and/or cell migration and therefore preventing and/or treating cancer comprising administering to a subject in need thereof a composition comprising one or more CG 55069 proteins or an antibody thereto.
  • the present invention provides an isolated protein selected from the group consisting of: (a) a protein comprising an amino acid sequence of SEQ ID NOs:2, 4-, 6, 8, 10, 12, 14, 16, 18, or 20; (b) a protein with one or more amino acid substitutions to the protein of (a), wherein said substitutions are no more than 15% of the amino acid sequence of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, or 20, and wherein said protein with one or more amino acid substitutions retains antiangiogenic activity; and (c) a fragment of the protein of (a) or (b), which fragment retains antiangiogenic and/or inhibits cell migration activity.
  • the present invention provides an isolated nucleic acid m olecule selected from the group consisting of: (a) a nucleic acid molecule comprising a nucleotides sequence selected from the group consisting of SEQ ID NOs: 1 , 3, 5, 7, 9, 11 , 13, 15, 17 and 19; (b) a nucleic acid molecule encoding a protein comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 , 3, 5, 7, 9, 11 , 13, 15, 17 and 19 and (c) a nucleic acid molecule hybridizes under stringent conditions to a nucleotide sequence of SEQ ID NO: 1 , 3, 5, 7, 9, 11 , 13, 15, 17 or 19 or a complement of said nucleic acid molecule.
  • the stringent conditions comprise a salt concentration from about 0.1 M to about 1.0 M sodium ion, a pH from about 7.0 to about 8.3, a temperature is at least about 60oC, and at least one wash in 0.2 X SSC, 0.01% BSA.
  • the present invention provides an isolated antibody with specificity to a protein selected from the group consisting of a protein comprising an amino acid seque nee of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, or 20; or a fragment of the antibody which fragment retains the specific binding activity.
  • one or more CG55069 proteins are isolated from a cultured eukaryotic cell.
  • one or more CG55069 proteins are isolated from a cultured prokaryotic cell. In a preferred embodiment, one or more CG55069 proteins are isolated from E. coli. In a specific embodiment, one or more CG55069 proteins isolated from a cultured host cell has a purity of at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%.
  • the present invention provides methods of preventing angiogenesis and/or cell migration and therefore preventing and/or treating cancer comprising administering to a subject in need thereof a prophylactically and/or therapeutically effective amount of an isolated protein selected from the group consisting of: (a) a protein comprising an amino acid sequence of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, or 20; (b) a protein with one or more amino ac id substitutions to the protein of (a), wherein said substitutions are no more than 15% of th& amino acid sequence of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, or 20, and wherein said protein with one or more amino acid substitutions retains antiangiogenic activity; and (c) a fragment o-f the protein of (a) or (b), which fragment retains antiangiogenic and/or inhibits cell migration activity.
  • an isolated protein selected from the group consisting of: (a) a protein comprising an amino acid sequence of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, or
  • the present invention provides methods of preventing angiogenesis and/or cell migration and therefore preventing and/or treating cancer comprising administering to a subject in need thereof a prophylactically or therapeutically effective amount of a protein isolated from a cultured host cell containing an isolated nucleic acid molecule selected from the group consisting of: (a) a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1 , 3, 5, 7, 9, 11 , 13, 15, 17 and 19; (b) a nucleic acid molecule encoding a protein comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 , 3, 5, 7, 9, 11 , 13, 15, 17 and 19; and (c) a nucleic acid molecule hybridizes under stringent conditions to a nucleotide sequence of SEQ ID NO: 1 , 3, 5, 7, 9, 11 , 13, 15, 17 or 19, or a complement of said nucleic acid molecule.
  • preventing angiogenesis and/or cell migration and therefore preventing and/or treating cancers include, but is not limited to, neuroblastoma, renal carcinoma, fibrosarcoma, rhabdosarcoma, glioblastoma, lung cancer or pancreatic cancer.
  • Cell migration, angiogenesis or actin filament formation is inhibited by contacting or introducing to a cell or tissue a composition containing a CG55069 polypeptide, polynucleotide or antibody.
  • the invention also features methods of preventing or alleviating a symptom of cell migration/angiogenesis related disorder in a subject by administering to the subject a CG55069 polypeptide, polypeptide or antibody.
  • Migrating cells or cells influencing angiogenic activity may be normal or cancerous.
  • the cell is an endotheiial cell, an epithelial cell, a neuronal cell, a mesenchymal cell or a fibroblast.
  • the cell may be a neuroblastoma cell, a renal carcinoma cell, a fibrosarcoma cell, a rhabdosarcoma cell, a glioblastoma, a lung cancer cell or a pancreatic cancer cell.
  • the subject may be a mammal such as human. The subject is suffering from or at risk of developing cell migration/angiogenesis related disorder.
  • Cell migration/angiogenesis related disorders include for example, diseases that cause neovascularization, cancer such neuroblastoma, renal carcinoma, fibrosarcoma, rhabdosarcoma and pancreatic cancer, wound healing, or tissue regeneration.
  • the invention further provides chimeric proteins.
  • the chimeric proteins include a first and a second polypeptide.
  • the first polypeptide includes a CG55069 polypeptide.
  • the second polypeptide for example, is a portion of an immunoglobulin molecule.
  • the portion of the immunoglobulin molecule includes for example the V5 region of the immunoglobulin molecule.
  • a chimeric protein of the invention may be CG55069-18 or CG55069-19.
  • the invention also provides methods for treating or preventing cancer such as renal cell carcinoma, prostate carcinoma, thyroid carcinoma, ovarian carcinoma, glioblastoma and lung carcinoma, in mammals, by administering a compound that inhibits Ten-M3.
  • Compounds that inhibit Ten-M3 include proteins that bind to Ten-M3 protein.
  • Examples of compounds that bind Ten-M3 include fragments of the protein or Ten-M3 specific antibodies that antagonize the function of endogenous Ten-M3.
  • this invention discloses the use of a fragment of the Ten-M3 protein, CG55069-04 and CG55069-11 , that inhibits the cell motility function of Ten- M3.
  • Figure 1 is a schematic outline of the regions of the Ten-M3 protein and the region expressed and purified and used in the assays described herein.
  • Figure 2 shows Coomassie blue stained polyacrylamide gel of CG55069 protein purified from transfected human embryonic kidney cells.
  • Figure 3 is a histogram illustrating CG55069 inhibition of A) HUVEC, B) HMVEC, C) 786-0 and D) H1299 cell migration in a dose dependent manner.
  • Figure 4 is a histogram illustrating CG55069-11 antiangiogenic activity in terms of effect on A) vessel nodes B) vessel ends and C) vessel length in a matrigel plug assay.
  • Figure 5 FACs analysis showing CG55069 binding to 786-0 cells (A) ; in competition with heparin sulfate (B) ; U87 cells (C) ; and HUVEC cells (D).
  • Figure 6 shows results of targeted cell killing in CG55069 expressing (A) and CG55069 negative (B) cells.
  • CG55069 refers to a class of proteins (including peptides and polypeptides) or nucleic acids encoding such proteins or their complementary strands, where the proteins comprise an amino acid sequence of SEQ ID NO: 2, or its fragments, derivatives, variants, homologs, or analogs.
  • a CG55069 protein retains at least some biological activity of Ten-M3.
  • biological activity means that a CG55069 protein possesses some but not necessarily all the same properties of (and not necessarily to the same degree as) Ten-M3.
  • a member (e.g., a protein and/or a nucleic acid encoding the protein) of the CG55069 family may further be given an identification name.
  • CG55069-01 SEQ ID NOs:7 and 8) represents the first identified Ten-M4 (see U.S. Patent Application No ⁇ 10/038,854);
  • CG55069-17 (SEQ ID NO. 2) represents the full length cloned protein encoded by the nucleic acid molecule SEQ ID NO. 1.
  • a mature polypeptide results by one or more naturally occurring processing steps that may take place within the cell in which the gene product arises.
  • the mature form may arise as a result of cleavage of the N-terminal methionine residue or N-terminal signal sequence, or post-translationai modification such as glycosylation, myristylation or phosphorylation.
  • the extracellular domain (ECD) exemplified by CG55069-16 (SEQ ID NO. 4) encompasses the EGF repeats and the C-terminai globular domain.
  • the EGF domain is exemplified by amino acid sequences of CG55069-04 (SEQ ID NO. 12); N-terminal EGF domain is exemplified by amino acid sequences of CG55069-11 (SEQ ID NO. 6). It is shown herein that the EGF domains CG55069-04 and CG55069-11 inhibit endothelial cell migration and reduce angiogenesis and thus could be used in the prevention and/or treatment of cancer.
  • Table 1 shows a summary of some of the CG55069 family members.
  • the invention includes a variant of Ten-M3 protein, in which some amino acids residues, e.g., no more than 1%, 2%, 3%, 5%, 10% or 15% of the amino acid sequence of Ten- M3 (SEQ ID NO:2), are changed.
  • the invention includes nucleic acid molecules that can hybridize to Ten-M3 under stringent hybridization conditions. Table 1. Summary of CG55069 family members
  • the term "effective amount” refers to the amount of a therapy ⁇ e.g., a composition comprising a CG55069 protein) which is sufficient to reduce and/or ameliorate the severity and/or duration of cancer or one or more symptoms thereof, prevent the advancement of, cause regression of, prevent the recurrence, development, or onset of one or more symptoms associated with cancer, or enhance or improve the prophylactic or therapeutic effect(s) of another therapy.
  • a therapy ⁇ e.g., a composition comprising a CG55069 protein
  • hybridizes under stringent conditions describes conditions for hybridization and washing under which nucleotide sequences at least 30% (preferably, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 98%) identical to each other typically remain hybridized to each other.
  • stringent conditions are known to those skilled in the art and can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1 -6.3.6.
  • stringent hybridization conditions comprise a salt concentration from about 0.1 M to about 1.0 M sodium ion, a pH from about 7.0 to about 8.3, a temperature is at least about 60°C, and at least one wash in 0.2 X SSC, 0.01 % BSA.
  • stringent hybridization conditions are hybridization at 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.1XSSC, 0.2% SDS at about 68 °C.
  • stringent hybridization conditions are hybridization in 6XSSC at about 45°C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65°C ⁇ i.e., one or more washes at 50°C, 55°C, 60°C or 65°C). It is understood that the nucleic acids of the invention do not include nucleic acid molecules that hybridize under these conditions solely to a nucleotide sequence consisting of only A or T nucleotides.
  • the term "isolated" in the context of a protein agent refers to a protein agent that is substantially free of cellular material or contaminating proteins from the cell or tissue source from which it is derived, or substantially free of chemical precursors or other chemicals when chemically synthesized.
  • substantially free of cellular material includes preparations of a protein agent in which the protein agent is separated from cellular components of the cells from which it is isolated or recombinantly produced.
  • a protein agent that is substantially free of cellular material includes preparations of a protein agent having less than about 30%, 20%, 10%, or 5% (by dry weight) of host cell proteins (also referred to as a
  • contaminating proteins When the protein agent is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, 10%, or 5% of the volume of the protein agent preparation.
  • culture medium represents less than about 20%, 10%, or 5% of the volume of the protein agent preparation.
  • the protein agent When the protein agent is produced by chemical synthesis, it is preferably substantially free of chemical precursors or other chemicals, i.e., it is separated from chemical precursors or other chemicals that are involved in the synthesis of the protein agent. Accordingly, such preparations of a protein agent have less than about 30%, 20%, 10%, 5% (by dry weight) of chemical precursors or compounds other than the protein agent of interest.
  • protein agents disclosed herein are isolated.
  • nucleic acid molecules refers to a nucleic acid molecule that is separated from other nucleic acid molecules that are present in the natural source of the nucleic acid molecule.
  • an "isolated" nucleic acid molecule such as a cDNA molecule, can be substantially free of other cellular material or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.
  • nucleic acid molecules are isolated.
  • the terms “prevent,” “preventing,” and “prevention” refer to the prevention of the recurrence, onset, or development of cancer or one or more symptoms thereof in a subject resulting from the administration of a therapy ⁇ e.g., a composition comprising a CG55069 or an antibody thereto), or the administration of a combination of therapies.
  • a therapy e.g., a composition comprising a CG55069 or an antibody thereto
  • prophylactically effective amount refers to the amount of a therapy ⁇ e.g., a composition comprising a CG55069 protein) which is sufficient to result in the prevention of the development, recurrence, or onset of cancer or one or more symptoms thereof, or to enhance or improve the prophylactic effect(s) of another therapy.
  • the terms “subject” and “subjects” refer to an animal, preferably a mammal, including a non-primate (e.g., a cow, pig, horse, cat, or dog), a primate ⁇ e.g., a monkey, chimpanzee, or human), and more preferably a human.
  • the subject is a mammal, preferably a human, who has or is at risk of developing cancer.
  • the subject is a farm animal ⁇ e.g., a horse, pig, or cow) or a pet ⁇ e.g., a dog or cat) that has or is at risk of developing cancer.
  • the term "subject” is used interchangeably with “patient” in the present invention.
  • the terms “treat,” “treatment,” and “treating” refer to the reduction of the progression, severity, and/or duration of cancer or amelioration of one or more symptoms thereof, wherein such reduction and/or amelioration result from the administration of one or more therapies ⁇ e.g., a composition comprising a CG55069 protein or antibody thereto).
  • the term "therapeutically effective amount” refers to the amount of a therapy ⁇ e.g., a composition comprising a CG55069 protein), which is sufficient to reduce the severity of, reduce the duration of, prevent the advancement of, cause regression of, ameliorate one or more symptoms associated with, cancer, or enhance or improve the therapeutic effect(s) of another therapy.
  • a therapy e.g., a composition comprising a CG55069 protein
  • antibody refers to an immunoglobulin or a fragment or a derivative thereof, and encompasses any polypeptide comprising an antigen- binding site, regardless whether it is produced in vitro or in vivo.
  • antibody also includes antibody fragments such as Fab, F(ab') 2 , Fv, scFv, Fd, dAb, and other antibody fragments that retain antigen-binding function, i.e., the ability to bind CG55069 specifically. Typically, such fragments would comprise an antigen-binding domain.
  • compositions comprising CG55069 for prevention of angiogenesis and/or cell migration and thereby for treatment of cancer.
  • CG55069 refers to a class of proteins (including peptides and polypeptides) or nucleic acids encoding such proteins or their complementary strands, where the proteins comprise an amino acid sequence of SEQ ID NO:2, or its fragments, derivatives, variants, homologs, or analogs.
  • a CG55069 protein is a variant of Ten-M3. It will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of the Ten-M3 protein may exist within a population ⁇ e.g., the human population).
  • Such genetic polymorphism in the Ten-M3 gene may exist among individuals within a population due to natural allelic variation. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the Ten-M3 gene. Any and all such nucleotide variations and resulting amino acid polymorphisms in the Ten-M3 protein, which are the result of natural allelic variation of the Ten-M3 protein, are intended to be within the scope of the invention.
  • the invention provides a fragment of a Ten-M3 protein, including fragments of variant Ten-M3 proteins, mature Ten-M3 proteins, and variants of mature Ten-M3 proteins, as well as Ten-M3 proteins encoded by allelic variants and single nucleotide polymorphisms of Ten-M3 nucleic acids.
  • An example of an Ten-M3 protein fragment includes, but is not limited to, residues 1-308, 1-544, 1-575, 1-609, 1-641 , 1-676, 1-685, 1-707, 1 -730, 1- 738, 1-782, 1-1209, 1-1324, 1-1384, 1-1445, 1-1514, 1-1600, 1-1664, 1-1801 , 1-1875, 1-1982, 1- 2207, 1-2261 , 1-2715, 10-308, 10-544, 10-575, 10-609, 10-641 , 10-676, 10-685, 10-707, 10-730, 10-738, 1-782, 10-1209, 10-1324, 10-1384, 10-1445, 10-1514, 10-1600, 10-1664, 10-1801, 10- 1875, 10-1982, 10-2207, 10-2261 , 10-2715, 325-544, 325-575, 325-609, 325-641 , 325-676, 325- 685, 325-707, 325-730,
  • the invention also encompasses derivatives and analogs of Ten-M3.
  • the production and use of derivatives and analogs related to Ten-M3 are within the scope of the present invention.
  • the derivative or analog is functionally active, i.e., capable of exhibiting one or more functional activities associated with a full-length, wild-type Ten-M3.
  • Derivatives or analogs of Ten-M3 can be tested for the desired activity by procedures known in the art, including but not limited to, using appropriate cell lines, animal models, and clinical trials.
  • Ten-M3 derivatives can be made via altering Ten-M3 sequences by substitutions, insertions or deletions that provide for functionally equivalent molecules.
  • such alteration of an Ten-M3 sequence is done in a region that is not conserved in the Ten-M3 protein family.
  • nucleotide coding sequences Due to the degeneracy of nucleotide coding sequences, other DNA sequences which encode substantially the same amino acid sequence as Ten-M3 may be used in the practice of the present invention. These include, but are not limited to, nucleic acid sequences comprising all or portions of Ten-M3 which are altered by the substitution of different codons that encode a functionally equivalent amino acid residue within the sequence, thus producing a silent change.
  • a wild-type Ten-M3 nucleic acid sequence is SEQ ID NO:1.
  • the Ten-M3 derivatives of the invention include, but are not limited to, those containing, as a primary amino acid sequence, all or part of the amino acid sequence of Ten-M3 including altered sequences in which functionally equivalent amino acid residues are substituted for residues within the sequence resulting in a silent change.
  • one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity which acts as a functional equivalent, resulting in a silent alteration.
  • Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs.
  • nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine.
  • polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine.
  • the positively charged (basic) amino acids include arginine, lysine and histidine.
  • the negatively charged (acidic) amino acids include aspartic acid and glutamic acid.
  • Ten-M3 derivatives of the invention also include, but are not limited to, those containing, as a primary amino acid sequence, all or part of the amino acid sequence of Ten-M3 including altered sequences in which amino acid residues are substituted for residues with similar chemical properties. In a specific embodiment, 1 , 2, 3, 4, or 5 amino acids are substituted.
  • Ten-M3 Derivatives or analogs of Ten-M3 include, but are not limited to, those proteins which are substantially homologous to Ten-M3 or fragments thereof, or whose encoding nucleic acid is capable of hybridizing to the Ten-M3 nucleic acid sequence.
  • the Ten-M3 derivatives and analogs of the invention can be produced by various methods known in the art. The manipulations which result in their production can occur at the gene or protein level.
  • the cloned Ten-M3 gene sequence can be modified by any of numerous strategies known in the art (e.g., Maniatis, T., 1989, Molecular Cloning, A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.).
  • the sequence can be cleaved at appropriate sites with restriction endonuclease(s), followed by further enzymatic modification if desired, isolated, and ligated in vitro.
  • the Ten-M3-encoding nucleic acid sequence can be mutated in vitro or in vivo, to create and/or destroy translation, initiation, and/or termination sequences, or to create variations in coding regions and/or form new restriction endonuclease sites or destroy preexisting ones, to facilitate further in vitro modification.
  • Any technique for mutagenesis known in the art can be used, including but not limited to, in vitro site-directed mutagenesis (Hutchinson, C. etal., 1978, J. Biol. Chem 253:6551), use of TAB.RTM. linkers (Pharmacia), etc.
  • Manipulations of the Ten-M3 sequence may also be made at the protein level.
  • Ten-M3 fragments or other derivatives or analogs which are differentially modified during or after translation, e.g., by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc.
  • any of numerous chemical modifications may be carried out by known techniques, including but not limited to, reagents useful for protection or modification of free NH2- groups, free COOH- groups, OH- groups, side groups of Trp-, Tyr-, Phe-, His-, Arg-, or Lys-; specific chemical cleavage by cyanogen bromide, hydroxylamine, BNPS-Skatole, acid, or alkali hydrolysis; enzymatic cleavage by trypsin, chymotrypsin, papain, V8 protease, NaBH4; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; etc.
  • analogs and derivatives of Ten-M3 can be chemically synthesized.
  • a protein corresponding to a portion of Ten-M3 which comprises the desired domain, or which mediates the desired aggregation activity in vitro, or binding to a receptor can be synthesized by use of a peptide synthesizer.
  • nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the Ten-M3 sequence.
  • Non-classical amino acids include, but are not limited to, the D-isomers of the common amino acids, ⁇ -amino isobutyric acid, 4-aminobutyric acid, hydroxyproline, sarcosine, citrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, ⁇ -alanine, designer amino acids such as ⁇ -methyl amino acids, C ⁇ -methyl amino acids, and N ⁇ -methyl amino acids.
  • the Ten-M3 derivative is a chimeric or fusion protein comprising Ten-M3 or a fragment thereof fused via a peptide bond at its amino- and/or carboxy- terminus to a non-Ten -M3 amino acid sequence.
  • the non-Ten-M3 amino acid sequence is fused at the amino-terminus of an Ten-M3 or a fragment thereof.
  • such a chimeric protein is produced by recombinant expression of a nucleic acid encoding the protein (comprising an Ten-M3-coding sequence joined in-frame to a non-Ten-M3 coding sequence).
  • Such a chimeric product can be custom made by a variety of companies ⁇ e.g., Retrogen, Operon, etc.) or made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other by methods known in the art, in the proper coding frame, and expressing the chimeric product by methods commonly known in the art.
  • a chimeric product may be made by protein synthetic techniques, e.g., by use of a peptide synthesizer.
  • a chimeric nucleic acid encoding Ten-M3 with a heterologous signal sequence is expressed such that the chimeric protein is expressed and processed by the cell to the mature Ten-M3 protein.
  • the rimary sequence of Ten-M3 and non- Ten-M3 gene may also be used to predict tertiary structure of the molecules using computer simulation (Hopp and Woods, 1981 , Proc. Natl. Acad. Sci. U.S.A. 78:3824-3828); the chimeric recombinant genes could be designed in light of correlations between tertiary structure and biological function. Likewise, chimeric genes comprising an essential portion of Ten-M3 molecule fused to a heterologous (non-Ten-M3) protein-encoding sequence may be constructed.
  • such chimeric construction can be used to enhance one or more desired properties of an Ten-M3, including but not limited to, Ten-M3 stability, solubility, or resistance to proteases.
  • chimeric construction can be used to target Ten-M3 to a specific site.
  • chimeric construction can be used to identify or purify an Ten-M3 of the invention, such as a His-tag, a FLAG tag, a green fluorescence protein (GFP), ⁇ -galactosidase, a maltose binding protein (MalE), a cellulose binding protein (CenA) or a mannose protein, etc.
  • GFP green fluorescence protein
  • MalE maltose binding protein
  • CenA cellulose binding protein
  • a CG55069 protein can be modified so that it has improved solubility and/or an extended half-life in vivo using any methods known in the art.
  • Fc fragment of human IgG, or inert polymer molecules such as high molecular weight polyethyleneglycol (PEG) can be attached to a CG55069 rotein with or without a multifunctional linker either through site-specific conjugation of the PEG to the N- or C-terminus of the protein or via epsilon-amino groups present on lysine residues. Linear or branched polymer derivatization that results in minimal loss of biological activity will be used.
  • the degree of conjugation can be closely monitored by SDS-PAGE and mass spectrometry to ensure proper conjugation of PEG molecules to the CG55069 protein.
  • Unreacted PEG can be separated from CG55069-PEG conjugates by size-exclusion or by ion-exchange chromatography.
  • PEG-derivatized conjugates can be tested for in vivo efficacy using methods known to those of skill in the art.
  • a CG55069 protein can also be conjugated to albumin in order to make the protein more stable in vivo or have a longer half life in vivo. The techniques are well known in the art, see e.g., International Publication Nos. WO 93/15199, WO 93/15200, and WO 01/77137; and European Patent No.
  • CG55069 refers to: CG55069-17 (SEQ ID NOs:1 and 2), G55069- 16 (SEQ ID NOs:3 and 4), CG55069-11 (SEQ ID NOs:5 and 6), CG55069-01 (SEQ ID NOs:7 and 8), CG55069-02 (SEQ ID NOs:9 and 10), CG55069-04 (SEQ ID NOs:11 and 12), CG55069-07 (SEQ ID NOs:13 and 14), CG55069-15 (SEQ ID NOs:15 and 16), CG55069-18 (SEQ ID NOs:17 and 18), and CG55069-19 (SEQ ID NOs: 19 and 20) or a combination thereof.
  • any techniques known in the art can be used in purifying a CG55069 protein, including but not limited to, separation by precipitation, separation by adsorption ⁇ e.g., column chromatography, membrane adsorbents, radial flow columns, batch adsorption, high-performance liquid chromatography, ion exchange chromatography, inorganic adsorbents, hydrophobic adsorbents, immobilized metal affinity chromatography, affinity chromatography), or separation in solution ⁇ e.g., gel filtration, electrophoresis, liquid phase partitioning, detergent partitioning, organic solvent extraction, and ultrafiltration). See e.g., Scopes, PROTEIN PURIFICATION,
  • CG55069 CG55069 proteins employed in a composition of the invention can be in the range of 80 to 100 percent of purity, or at least 80%, at least 85%, at least 90%, at least 95%, or at least 98% of purity. In one embodiment, one or more CG55069 proteins employed in a composition of the invention has a purity of at least 99%.
  • CG55069 is purified to apparent homogeneity, as assayed, e.g., by sodium dodecyl sulfate polyacrylamide gel electrophoresis. Methods known in the art can be utilized to recombinantly produce CG55069 proteins.
  • a nucleic acid sequence encoding a CG55069 protein can be inserted into an expression vector for propagation and expression in host cells.
  • An expression construct refers to a nucleic acid sequence encoding a CG55069 protein operably associated with one or more regulatory regions that enable expression of a CG55069 protein in an appropriate host cell.
  • “Operably-associated” refers to an association in which the regulatory regions and the CG55069 sequence to be expressed are joined and positioned in such a way as to permit transcription, and ultimately, translation.
  • the regulatory regions that are necessary for transcription of CG55069 can be provided by the expression vector.
  • a translation initiation codon (ATG) may also be provided if a CG55069 gene sequence lacking its cognate initiation codon is to be expressed.
  • cellular transcriptional factors such as RNA polymerase, will bind to the regulatory regions on the expression construct to effect transcription of the modified CG55069 sequence in the host organism.
  • the precise nature of the regulatory regions needed for gene expression may vary from host cell to host cell.
  • a promoter is required which is capable of binding RNA polymerase and promoting the transcription of an operably-associated nucleic acid sequence.
  • Such regulatory regions may include those 5' non-coding sequences involved with initiation of transcription and translation, such as the TATA box, capping sequence, CAAT sequence, and the like.
  • the non-coding region 3' to the coding sequence may contain transcriptional termination regulatory sequences, such as terminators and polyadenylation sites.
  • linkers or adapters providing the appropriate compatible restriction sites may be ligated to the ends of the cDNAs by techniques well known in the art (see e.g., Wu etal., 1987, Methods in Enzymol, 152:343-349). Cleavage with a restriction enzyme can be followed by modification to create blunt ends by digesting back or filling in single-stranded DNA termini before ligation. Alternatively, a desired restriction enzyme site can be introduced into a fragment of DNA by amplification of the DNA using PCR with primers containing the desired restriction enzyme site.
  • An expression construct comprising a CG55069 sequence operably associated with regulatory regions can be directly introduced into appropriate host cells for expression and production of a CG55069 protein without further cloning. See, e.g., U.S. Patent No. 5,580,859.
  • the expression constructs can also contain DNA sequences that facilitate integration of a CG55069 sequence into the genome of the host cell, e.g., via homologous recombination. In this instance, it is not necessary to employ an expression vector comprising a replication origin suitable for appropriate host cells in order to propagate and express CG55069 in the host eel Is.
  • a variety of expression vectors may be used, including but are not limited to, plasmids, cosmids, phage, phagemids or modified viruses.
  • host-expression systems represent vehicles by which the coding sequences of a CG55069 gene may be produced and subsequently purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, express CG55069 in situ.
  • microorganisms such as bacteria ⁇ e.g., E. coli and B.
  • subtilis transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing CG55069 coding sequences; yeast ⁇ e.g., Saccharomyces, Pichia) transformed with recombinant yeast expression vectors containing CG55069 coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing CG55069 coding sequences; plant cell systems infected with recombinant virus expression vectors ⁇ e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors ⁇ e.g., Ti plasmid) containing CG55069 coding sequences; or mammalian cell systems ⁇ e.g., COS, CHO, BHK, 293, NSO, and 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian
  • bacterial cells such as Escherichia coli and eukaryotic cells are used for the expression of a recombinant CG55069 molecule.
  • mammalian cells such as Chinese hamster ovary cells (CHO) can be used with a vector bearing promoter element from major intermediate early gene of cytomegalovirus for effective expression of a CG55069 sequence (Foecking etal., 1986, Gene 45:101 ; and Cockett etal., 1990, Bio/Technology 8:2).
  • a number of expression vectors may be advantageously selected depending upon the use intended for the CG55069 molecule being expressed.
  • vectors that direct the expression of high levels of fusion protein products that are readily purified may be desirable.
  • Such vectors include, but are not limited to, the E. coli expression vector pCR2.1 TOPO (Invitrogen); plN vectors (Inouye & Inouye, 1985, Nucleic Acids Res. 1 3:3101-3109; Van Heeke & Schuster, 1989, J. Biol. Chem. 24-:5503- 5509) and the like.
  • pFLAG Sigma
  • pMAL NEB
  • pET Novagen
  • GST glutathione 5-transferase
  • fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to matrix glutathione agarose beads followed by elution in the presence of free glutathione.
  • the pGEX vectors are designed to include throm in or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.
  • many vectors to express foreign genes can be used, e.g., Autographa californica nuclear polyhedrosis virus (AcNPV) can be used as a vector to express foreign genes. The virus grows in cells like Spodoptera frugiperda cells.
  • AcNPV Autographa californica nuclear polyhedrosis virus
  • a CG55069 coding sequence may be cloned individually into non-essential regions (e.g., the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (e.g., the polyhedrin promoter).
  • an AcNPV promoter e.g., the polyhedrin promoter
  • a number of viral-based expression systems may be utilized.
  • a CG55069 coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination.
  • Insertion in a non-essential region of the viral genome ⁇ e.g., region El or E3) will result in a recombinant virus that is viable and capable of expressing CG55069 in infected hosts (see, e.g., Logan & Shenk, 1984, Proc. Natl. Acad. Sci. USA 8 1 :355-359).
  • Specific initiation signals may also be required for efficient translation of inserted CG55069 coding sequences. These signals include the ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert.
  • These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic.
  • the efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see, e.g., Bittner et al., 1987, Methods in Enzymol. 153:51-544).
  • a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein.
  • Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed.
  • eukaryotic host cells that possess the cellular machinery for proper processing of the primary transcript and post-translational modification of the gene product, e.g., glycosylation and phosphorylation of the gene product, may be used.
  • mammalian host cells include, but are not limited to, PC12, CHO, VERY, BHK, Hela, COS, MDCK, 293, 3T3, W138, BT483, Hs578T, HTB2, BT20 and T47D, NSO (a murine myeloma cell line that does not endogenously produce any immunoglobulin chains), CRL7030 and HsS78Bst cells.
  • Expression in a bacterial or yeast system can be used if post- translational modifications are found to be non-essential for a desired activity of CG55069.
  • E. coli is used to express a CG55069 sequence.
  • stable expression in cells is preferred.
  • Cell lines that stably express CG55069 may be engineered by using a vector that contains a selectable marker.
  • engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media.
  • the selectable marker in the expression construct confers resistance to the selection and optimally allows cells to stably integrate the expression construct into their chromosomes and to grow in culture and to be expanded into cell lines. Such cells can be cultured for a long period of time while CG55069 is expressed contin uously.
  • a number of selection systems may be used, including but not limited to, antibiotic resistance (markers like Neo, which confers resistance to geneticine, or G-418 (Wu and Wu, 1991 , Biotherapy 3:87-95; Tolstoshev, 1993, Ann. Rev. Pharmacol. Toxicol. 32:573-596; Mulligan, 1993, Science 260:926-932; and Morgan and Anderson, 1993, Ann. Rev. Biochem.
  • mutant cell lines including, but not limited to, tk- , hgprt- or aprt- cells, can be used in combination with vectors bearing the corresponding genes for thymidine kinase, hypoxanthine, guanine- or adenine phosphoribosyltransferase. Methods commonly known in the art of recombinant DNA technology may be routinely applied to select the desired recombinant clone, and such methods are described, for example, in Ausubel et al.
  • the recombinant cells may be cultured under standard conditions of temperature, incubation time, optical density and media composition. However, conditions for growth of recombinant cells may be different from those for expression of CG55069. Modified culture conditions and media may also be used to enhance production of CG55069.
  • CG55069 Any techniques known in the art may be applied to establish the optimal conditions for producing CG55069.
  • An alternative to producing CG55069 or a fragment thereof by recombinant techniques is peptide synthesis.
  • an entire CG55069, or a protein corresponding to a portion of CG55069 can be synthesized by use of a peptide synthesizer.
  • Conventional peptide synthesis or other synthetic protocols well known in the art may be used.
  • Proteins having the amino acid sequence of CG55069 or a portion thereof may be synthesized by solid-phase peptide synthesis using procedures similar to those described by Merrifield, 1963, J. Am. Chem. Soc, 85:2149.
  • N- ⁇ -protected amino acids having protected side chains are added stepwise to a growing polypeptide chain linked by its C- terminal and to an insoluble polymeric support, i.e., polystyrene beads.
  • the proteins are synthesized by linking an amino group of an N- ⁇ -deprotected amino acid to an ⁇ -carboxyl group of an N- ⁇ -protected amino acid that has been activated by reacting it with a reagent such as dicyclohexylcarbodiimide. The attachment of a free amino group to the activated carboxyl leads to peptide bond formation.
  • the most commonly used N- ⁇ -protecting groups include Boc, which is acid labile, and Fmoc, which is base labile.
  • CG55069 ACTIVITIES Any methods known in the art can be used to determine the identity of a purified CG55069 protein in a composition used in accordance to the instant invention. Such methods include, but are not limited to, Western Blot, sequencing (e.g., Edman sequencing), liquid chromatography (e.g., HPLC, RP-HPLC with both UV and electrospray mass spectrometric detection), mass spectrometry, total amino acid analysis, peptide mapping, and SDS-PAGE.
  • sequencing e.g., Edman sequencing
  • liquid chromatography e.g., HPLC, RP-HPLC with both UV and electrospray mass spectrometric detection
  • mass spectrometry e.g., total amino acid analysis, peptide mapping, and SDS-PAGE.
  • the secondary, tertiary and/or quaternary structure of a CG55069 protein can analyzed by any methods known in the art, e.g., far UV circular dichroism spectrum can be used to analyze the secondary structure, near UV circular dichroism spectroscopy and second derivative UV absorbance spectroscopy can be used to analyze the tertiary structure, and light scattering SEC- HPLC can be used to analyze quaternary structure
  • the purity of a CG55069 protein in a composition used in accordance to the instant invention can be analyzed by any methods known in the art, such as but not limited to, sodium dodecyl sulphate polyacrylamide gel electrophoresis ("SDS-PAGE"), reversed phase high- performance liquid chromatography (“RP-HPLC”), size exclusion high-performance liquid chromatography (“SEC-HPLC”), and Western Blot (e.g., host cell protein Western Blot).
  • SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophor
  • a CG55069 protein in a composition used in accordance to the instant invention is at least 97%, at least 98%, or at least 99% pure by densitometry. In another preferred embodiment, a CG55069 protein in a composition used in accordance to the instant invention is more than 97%, more than 98%, or more than 99% pure by densitometry.
  • the biological activities and/or potency of CG55069 used in accordance with the present invention can be determined by any methods known in the art. For example, compositions for use in therapy in accordance to the methods of the present invention can be tested in suitable cell lines for one or more activities that Ten-M3 possesses (e.g., antiangiogenic, inhibition of cell migration activity).
  • compositions for use in a therapy in accordance to the methods of the present invention can also be tested in suitable animal model systems prior to testing in humans.
  • animal model systems include, but are not limited to, mucositis models in rats, mice, hamsters, chicken, cows, monkeys, rabbits, etc.
  • mice oral mucositis model Xu et al., Radiother Oncol 1 :369-374 (1984); hamster oral mucositis model, Sonis, In: Teicher B (ed) Tumor models in cancer research, Humana Press, Totowa, New Jersey (2002); rat gastrointestinal mucositis model, Gibson et al., J Gastroenterol Hepato 18:1095-1 100 (2003); mouse intestinal stem cells, Potten et al., Gut 36(6):864-873 (1995).
  • an index can be developed that combines observational examination of the animals as well as their survival status.
  • Any staging/scoring system for human patients known in the art may also be used to evaluate the effectiveness of the compositions of the invention.
  • any assays known to those skilled in the art can be used to evaluate the prophylactic and/or therapeutic utilities of the combinatorial therapies disclosed herein.
  • the effectiveness of CG55069 on preventing and/or treating disease can be monitored by any methods known to one skilled in the art.
  • the present invention provides methods of preventing angiogenesis and/or cell migration and therefore preventing and/or treating cancer comprising administering to a subject in need thereof an effective amount of a composition comprising one or more isolated CG55069 proteins or an antibody thereto.
  • Malignant conditions that can be prevented and/or treated by the methods of the invention includes, but is not limited to, neuroblastoma, renal carcinoma, fibrosarcoma, rhabdosarcoma, glioblastoma, lung cancer or pancreatic cancer.
  • the methods of the invention comprise administering an effective amount of a composition comprising one or more isolated CG55069 proteins to a subject.
  • the methods of the invention comprise administering an effective amount of a composition comprising an antibody to CG55069 to a subject.
  • the present invention provides methods of preventing angiogenesis and/or cell migration and therefore preventing and/or treating cancer in patient populations with or at risk to develop such cancers.
  • a composition comprising one or more isolated CG55069 proteins or antibodies thereto can also be used in combination with other therapies to prevent and/or treat disease.
  • a composition comprising one or more isolated CG55069 proteins is administered in combination with one or more other agents that have prophylactic and/or therapeutic effect(s) on preventing angiogenesis and/or cell migration and therefore preventing and/or treating cancer.
  • Toxicity and efficacy of the prophylactic and/or therapeutic protocols of the present invention can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD S0 (the dose lethal to 50% of the population) and the ED 50 (the dose therapeutically effective in 50% of the population).
  • the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD g ED j ,,.
  • Prophylactic and/or therapeutic agents that exhibit large therapeutic indices are preferred. While prophylactic and/or therapeutic agents that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such agents to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.
  • the data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage of the prophylactic and/or therapeutic agents for use in humans.
  • the dosage of such agents lies preferably within a range of circulating concentrations that include the ED 50 with little or no toxicity.
  • the dosage may -vary within this range depending upon the dosage form employed and the route of administration utilized.
  • the therapeutically effective dose can be estimated initially from cell culture assays.
  • a dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC 50 ⁇ i.e., the concentration of the test compound that achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful closes in humans.
  • Levels in plasma may be measured, for example, by high performance liquid chromatography.
  • the amount of the composition of the invention which will be effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques.
  • the precise dose to be employed in the formulation will also depend on the route of admin istration, and the seriousness of the disease or disorder, and should be decided according to the jj udgment of the practitioner and each patient's circumstances.
  • the dosage of a composition comprising one or more G53135 proteins for administration in a human patient provided by the present invention is at least 0.001 mg/kg, at least 0.005 mg/kg, at least 0.01 mg/kg, at least 0.03 mg/kg, at least 0.05 mg/kg, at least 0.1 mg/kg, at least 0.2 mg/kg, at least 0.3 mg/kg, at least 0.4 mg/kg, at least 0.5 mg/kg, at least 0.6 mg/kg, at least 0.7 mg/kg, at least 0.8 mg/kg, at least 0.9 mg/kg, at least 1 mg/kg, at least 2 mg/kg, at least 3 mg/kg, at least 4 mg/kg, at least 5 mg/kg, at least 6 mg/kg, at least 7 mg/kg, at least 8 mg/kg, at least 9 mg/kg, or at least 0 mg/kg (as measured by UV assay).
  • the dosage of a composition comprising one or more CG55069 proteins for administration in a human patient provided by the present invention is between 0.001-10 mg/kg, between 0.005-5 mg/kg, between 0.01-1 mg/kg, between 0.01-0.9 mg/kg, between 0.01-0.8 mg/kg, between 0.01-0.7 mg/kg, between O.01-0.6 mg/kg, between 0.01-0.5 mg/kg, or between 0.01 -0.3 mg/kg (as measured by UV assay).
  • Protein concentration can be measured by methods known in the art, such as Bradford assay or UV assay, and the concentration may vary depending on what assay is being used, in a non-limiting example, the protein concentration in a pharmaceutical composition of the instant invention is measured by a UV assay that uses a direct measurement of the UV absorption at a wavelength of 280 nm, and calibration with a well characterized reference standard of CG55069 protein (instead of IgG). Test results obtained with this UV method (using CG55069 reference standard) are three times lower than test results for the same sample(s) tested with the Bradford method (using IgG as calibrator).
  • a dosage of a composition comprising one or more CG55069 proteins for administration in a human patient provided by the present invention is between 0.001-10 mg/kg measured by UV assay, then the dosage is 0.003-30 mg/kg as measured by Bradford assay.
  • compositions used in accordance to the present invention can be administered to a subject at a prophylactically or therapeutically effective amount to prevent angiogenesis and/or cell migration and therefore preventing and/or treating cancer.
  • Various delivery systems are known and can be used to administer a composition used in accordance to the methods of the invention.
  • Such delivery systems include, but are not limited to, encapsulation in liposomes, microparticles, microcapsules, expression by recombinant cells, receptor-mediated endocytosis, construction of the nucleic acids of the invention as part of a retroviral or other vectors, etc.
  • compositions used in accordance to the methods of the invention may be administered by any convenient route, for example, by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., eye mucosa, oral mucosa, vaginal mucosa, rectal and intestinal mucosa, etc.), and may be administered together with other biologically active agents. Administration can be systemic or local.
  • the present invention comprises using single or double chambered syringes, preferably equipped with a needle-safety device and a sharper needle, that are pre- filled with a composition comprising one or more CG55069 proteins.
  • dual chambered syringes e.g., Vetter Lyo-Ject d ual-chambered syringe by Vetter Pharmar-Fertist
  • Such systems are desirable for lyophilized formulations, and are especially useful in an emergency setting.
  • This may be achieved by, for example, local infusion during surgery, or topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant (said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers).
  • administration can be by direct injection at the site (or former site) that are most sensitive
  • the composition of the invention is a nucleic acid encoding a prophylactic or therapeutic agent
  • the nucleic acid can be administered in vivo to promote expression of their encoded proteins (e.g., CG55069 proteins), by constructing the nucleic acid as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by use of a retroviral vector, or by direct injection, or by use of microparticle bombardment (e.g., a gene gun), or coating with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox-like peptide which is known to enter the nucleus, etc.
  • their encoded proteins e.g., CG55069 proteins
  • a nucleic acid of the invention can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination.
  • the instant invention encompasses bulk drug compositions useful in the manufacture of pharmaceutical compositions that can be used in the preparation of unit dosage forms.
  • a composition of the invention is a pharmaceutical composition.
  • Such compositions comprise a prophylactically or therapeutically effective amount of CG55069, and a pharmaceutically acceptable carrier.
  • the pharmaceutical compositions are formulated to be suitable for the route of administration to a subject.
  • the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in tine U.S.
  • carrier refers to a diluent, adjuvant, bulking agent (e.g.,arginine in various salt forms, sulfobutyl ether Beta- cyclodextrin sodium, or sucrose), excipient, or vehicle with which CG55069 is administered.
  • Such pharmaceutical carriers can be sterile liquids, such as water and oils (e.g., oils of petroleum, animal, vegetable or synthetic origins, such as peanut oil, soybean oil, mineral oil, sesame oil and the like), or solid carriers, such as one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, or encapsulating material.
  • oils e.g., oils of petroleum, animal, vegetable or synthetic origins, such as peanut oil, soybean oil, mineral oil, sesame oil and the like
  • solid carriers such as one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, or encapsulating material.
  • Water is a preferred carrier when the pharmaceutical composition is administered intravenously.
  • Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
  • Suitable pharmaceutical excipients include, but are not limited to, starch or its synthetically modified derivatives such as hydroxyethyl starch, stearate salts, glycerol, glucose, lactose, sucrose, trehalose, gelatin, sulfobutyl ether Beta-cyclodextrin sodium, sodium chloride, glycerol, propylene, glycol, water, ethanol, or a combination thereof.
  • the composition if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
  • compositions comprising CG55069 may be formulated into any of many possible dosage forms such as, but not limited to, liquid, suspension, microemulsion , microcapsules, tablets, capsules, gel capsules, soft gels, pills, powders, enemas, sustained-release formulations and the like.
  • the compositions comprising CG55069 may also be formulated as suspensions in aqueous, non-aqueous or mixed media.
  • Aqueous suspensions may further contain substances that increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran.
  • the suspension may also contain stabilizers.
  • the composition can also be formulated as a suppository, with traditional binders and carriers such as triglycerides.
  • Oral formulation can include standard carriers, such as pharmaceutical grades of mannitol, lactose, starch or its synthetically modified derivatives such as hydroxyethyl starch, stearate salts, sodium saccharine, cellulose, magnesium carbonate a etc.
  • a pharmaceutical composition comprising CG55069 is formulated to be compatible with its intended route of administration.
  • the composition is formulated in accordance with routine procedures as a pharmaceutical composition adap»ted for intravenous, subcutaneous, intramuscular, oral, intranasal, intratumoral or topical admin ⁇ stration to human beings.
  • compositions for intravenous administration are solutions in sterile isotonic or hypertonic aqueous buffer.
  • the composition may also include a solubilizing agent and a local anesthetic such as benzyl alcohol or lidocaine to ease pain at the site of the injection.
  • a composition comprising CG55069 is to be administered topically, the composition can be formulated in the form of transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders.
  • Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirabl e.
  • Coated condoms, gloves and the like may also be useful.
  • Preferred topical formulations include de those in which the compositions of the invention are in admixture with a topical delivery agent, such as but not limited to, lipids, liposomes, micelles, emulsions, sphingomyelins, lipid-protein or lipid-peptide complexes, fatty acids, fatty acid esters, steroids, chelating agents and surfactants.
  • a topical delivery agent such as but not limited to, lipids, liposomes, micelles, emulsions, sphingomyelins, lipid-protein or lipid-peptide complexes, fatty acids, fatty acid esters, steroids, chelating agents and surfactants.
  • the compositions comprising CG55069 may be encapsulated within liposomes or may form complexes thereto, in particular to cationic liposomes. Alternatively, the compositions comprising CG55069 may be complexed to lipids, in particular to cationic lipids.
  • viscous to semi-solid or solid forms comprising a carrier or one or more excipients compatible with topical application and having a dynamic viscosity preferably greater than water are typically employed.
  • suitable topical dosage forms include sprayable aerosol preparations wherein the active ingredient, preferably in combination with a solid or liquid inert carrier, is packaged in a mixture with a pressurized volatile (e.g., a gaseous propellant, such as Freon or hydrofluorocarbons) or in a squeeze bottle.
  • a pressurized volatile e.g., a gaseous propellant, such as Freon or hydrofluorocarbons
  • Moisturizers or humectants can also be added to pharmaceutical compositions and dosage forms if desired. Examples of such additional ingredients are well-known in the art.
  • a composition comprising CG55069 can be formulated in an aerosol form, spray, mist or in the form of drops or powder if intranasal administration is preferred.
  • a composition comprising CG55069 can be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant (e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, other hydrofluorocarbons, carbon dioxide or other suitable gas).
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, other hydrofluorocarbons, carbon dioxide or other suitable gas.
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • Microcapsules for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as dissacharides or starch.
  • a suitable powder base such as dissacharides or starch.
  • One or more CG55069 proteins may also be formulated into a microcapsule with one or more polymers (e.g., hydroxyethyl starch) form the surface of the microcapsule.
  • Such formulations have benefits such as slow-release.
  • a composition comprising CG55069 can be formulated in the form of powders, granules, microparticulates, nanoparticulates, suspensions or solutions in water or non-aqueous media, capsules, gel capsules, sachets, tablets or minitablets if oral administration is preferred. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable.
  • Tablets or capsules can be prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinised maize starch, polyvinylpyrrolidone, or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose, or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc, or silica); disinte grants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate).
  • binding agents e.g., pregelatinised maize starch, polyvinylpyrrolidone, or hydroxypropyl methylcellulose
  • fillers e.g., lactose, microcrystalline cellulose, or calcium hydrogen phosphate
  • lubricants e.g., magnesium stearate, talc, or silica
  • disinte grants e.g., potato starch or sodium starch
  • Liquid preparations for oral administration may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives, or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol, or fractionated vegetable oils); and preservatives (e.g., methyl or propyl- p-hydroxybenzoates or sorbic acid).
  • suspending agents e.g., sorbitol syrup, cellulose derivatives, or hydrogenated edible fats
  • emulsifying agents e.g., lecithin or acacia
  • non-aqueous vehicles e.g., almond oil, oily esters, ethyl alcohol, or fractionated vegetable oils
  • preservatives e.g., methyl or propyl- p-hydroxybenzoates or sorbic acid
  • compositions of the invention are orally administered in conjunction with one or more penetration enhancers, e.g., alcohols, surfactants and chelators.
  • penetration enhancers include, but are not limited to, fatty acids and esters or salts thereof, bile acids and salts thereof.
  • combinations of penetration enhancers are used, e.g., alcohols, fatty acids/salts in combination with bile acids/salts.
  • sodium salt of lauric acid, capric acid is used in combination with UDCA.
  • compositions of the invention may be delivered orally in granular form including, but is not limited to, sprayed dried particles, or complexed to form micro or nanoparticles.
  • Complexing agents that can be used for complexing with the compositions of the invention include, but are not limited to, poly-amino acids, polyimines, polyacrylates, polyalkylacrylates, polyoxethanes, polyalkylcyanoacrylates, cationized gelatins, albumins, acrylates, polyethyleneglycols (PEG), DEAE-derivatized polyimines, pollulans, celluloses, and starches.
  • Particularly preferred complexing agents include, but are not limited to, chitosan, N-trimethylchitosan, poly-L-lysine, polyhistidine, polyomithine, polyspermines, protamine, polyvinyipyridine, polythiodiethylamino- methylethylene P(TDAE), polyaminostyrene (e.g.
  • a composition comprising CG55069 can be delivered to a subject by pulmonary administration, e.g., by use of an inhaler or nebulizer, of a composition formulated with an aerosolizing agent.
  • a composition comprising CG55069 is formulated for parenteral administration by injection (e.g., by bolus injection or continuous infusion).
  • Formulations for injection may be presented in unit dosage form (e.g., in ampoules or in multi- dose containers) with an added preservative.
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • the active ingredient may be in powder form for constitution with a suitable vehicle (e.g., sterile pyrogen-free water) before use.
  • a suitable vehicle e.g., sterile pyrogen-free water
  • the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings.
  • compositions for intravenous administration are solutions in sterile isotonic aqueous buffer.
  • the composition may also include a solubilizing agent and a local anesthetic such as benzyl alcohol or lidocaine to ease pain at the site of the injection.
  • the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a sealed container, such a-s a vial, ampoule or sachette, indicating the quantity of active agent.
  • a sealed container such as a-s a vial, ampoule or sachette, indicating the quantity of active agent.
  • the composition is to be administered by infusion, it can be dispensed with an infusion container containing sterile pharmaceutical grade water or saline.
  • an ampoule or vial of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.
  • a composition comprising CG55069 can be formulated as neutral or salt forms.
  • compositions comprising CG55069 may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection.
  • compositions may be formulated with suitable polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • Liposomes and emulsions are well known examples of delivery vehicles or carriers for hydrophilic drugs.
  • the ingredients of the compositions used in accordance to the methods of the invention are derived from a subject that is the same species origin or species reactivity as recipient of such compositions.
  • a formulation used in accordance to the methods of the invention comprises 0.02 M - 0.2 M acetate, 0.5-5% glycerol, 0.2-0.5 M arginine-HCI, and one ore more CG55069 proteins, preferably 0.5-5 mg/ml (UV).
  • a formulation used in accordance to the methods of the invention comprises 0.04M sodium acetate, 3% glycerol (volume/volume), 0.2 M arginine-HCI at pH 5.3, and one or more isolated CG55069 proteins, preferably 0.8 mg/ml (UV).
  • a formulation used in accordance to the methods of the invention comprises 0.01-1 M of a stabilizer, such as arginine in various salt forms, sulfobutyl ether Beta-cyclodextrin sodium, or sucrose, 0.01-0.1 M sodium phosphate monobasic (NaH 2 PO Pittsburgh-H 2 0), 0.01%-0.1% weight/volume ("w/v") polysorbate 80 or polysorbate 20, and one or more CG55069 proteins, preferably 0.005-50 mg/ml (UV).
  • a stabilizer such as arginine in various salt forms, sulfobutyl ether Beta-cyclodextrin sodium, or sucrose
  • w/v weight/volume
  • polysorbate 80 or polysorbate 20 preferably 0.005-50 mg/ml (UV).
  • a formulation used in accordance to the methods of the invention comprises 30mM sodium citrate, pH 6.1 , 2mM EDTA, 200mM sorbitol, 50mM KCI, 20% glycerol, and one or more isolated CG55069 proteins.
  • the invention also provides kits for carrying out the therapeutic regimens of the invention.
  • kits comprise in one or more containers prophylactically or therapeutically effective amounts of the composition of the invention (e.g., a composition comprising one or more CG55069 proteins) in pharmaceutically acceptable form.
  • the composition in a vial of a kit of the invention may be in the form of a pharmaceutically acceptable solution, e.g., in combination with sterile saline, dextrose solution, or buffered solution, or other pharmaceutically acceptable sterile fluid.
  • the composition may be lyophilized or desiccated; in this instance, the kit optionally further comprises in a container a pharmaceutically acceptable solution (e.g., saline, dextrose solution, etc.), preferably sterile, to reconstitute the composition to form a solution for injection purposes.
  • a kit of the invention further comprises a needle or syringe, preferably packaged in sterile form, for injecting the formulation, and/or a packaged alcohol pad. Instructions are optionally included for administration of the formulations of the invention by a clinician or by the patient.
  • kits comprising a plurality of containers each comprising a pharmaceutical formulation or composition comprising a dose of the composition of the invention (e.g., a composition comprising one or more CG55069 proteins) sufficient for a single administration.
  • the packaging material and container are designed to protect the stability of the product during storage and shipment.
  • compositions of the invention are stored in containers with biocompatible detergents, including but not limited to, lecithin, taurocholic acid, and cholesterol; or with other proteins, including but not limited to, gamma globulins and serum albumins.
  • the products of the invention include instructions for use or other informational material that advise the physician, technician, or patient on how to appropriately prevent or treat the disease or disorder in question.
  • Anti-CG55069 Antibodies Included in the invention are antibodies to CG55069 protein, or a fragment, derivative, fragment, analog, homolog or ortholog thereof. Such antibodies include, but are not limited to, immunoglobulin molecules and immunologically active portions of immunoglobulin (lg) molecules, i.e., molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen, polyclonal, monoclonal, chimeric, single chain, F ab , F ab' and F (ab' )2 fragments, and an F ⁇ expression library.
  • immunoglobulin immunoglobulin
  • Antibodies may be of the classes IgG, IgM, IgA, lgE and IgD, and include subclasses such as IgG ⁇ IgG 2 , and others.
  • the light chain may be a kappa chain or a lambda chain.
  • Reference herein to antibodies includes a reference to all such classes, subclasses and types of antibody species.
  • CG55069 full length protein or a portion or fragment thereof can be used as an immunogen to generate antibodies that immunospecifically bind the antigen, using standard techniques for polyclonal and monoclonal antibody preparation.
  • An antigenic peptide fragment comprises at least 6 amino acid residues of the amino acid sequence of the full length protein, and encompasses an epitope.
  • the antigenic peptide may comprise at least 10 amino acid residues, or at least 15, at least 20 canal or at least 30 amino acid residues.
  • Epitopes of the antigenic peptide are commonly regions of the protein that are located on its surface; often these are hydrophilic regions.
  • at least one epitope encompassed by the antigenic peptide is a region of CG55069 that is located on the surface of the protein, e.g., a hydrophilic region and can be determined by a hydrophobicity analysis of the protein sequence.
  • hydropathy plots showing regions of hydrophilicity and hydrophobicity can be generated by any method well known in the art (for example see Proc. Nat. Acad. Sci.
  • epitopic determinants includes any protein determinant capable of specific binding to an immunoglobulin or T-cell receptor. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics.
  • An anti-CG55069 antibody of the present invention is said to specifically bind to CG55069 when the equilibrium binding constant (K D ) is ⁇ 1 ⁇ M, preferably ⁇ 100 nM, more preferably ⁇ 10 nM, and most preferably ⁇ 100 pM to about 1 pM, as measured by assays including radioligand binding assays or similar assays known to skilled artisans.
  • K D equilibrium binding constant
  • Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies directed against a protein of the invention, or against derivatives, fragments, analogs homologs or orthologs thereof (see, for example, Antibodies: A Laboratory Manual, Harlow E, and Lane D, 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY).
  • CG55069 nucleic acid molecules are used directly for production of antibodies recognizing CG55069 polypeptides.
  • Antibodies can be prepared by genetic or DNA-based immunization. It has been shown that intramuscular immunization of mice with a naked DNA plasmid led to expression of reporter proteins in muscle cells (Science 247: 1465-1468, 1990) and that this technology could stimulate an immune response (Nature. 356: 152-154, 1992). The success of genetic immunization in stimulating both cellular and humoral immune responses has been widely reported (reviewed in: Annu. Rev. Immunol. 15: 617-648, 1997; Immunol. Today 19: 89-97, 1998; Annu. Rev. Immunol. 18: 927-974, 2000).
  • antibodies can be generated through immunization with a cDNA sequence encoding the protein in question.
  • the animal ' s immune system is activated in response to the synthesis of the foreign protein.
  • the quantity of protein produced in vivo following genetic immunization is within the picogram to nanogram range, which is much lower than the amounts of protein introduced by conventional immunization protocols.
  • a very efficient immune response is achieved due to the foreign protein being expressed directly in, or is quickly taken up by antigen-presenting dendritic cells (J. Leuk. Biol. 66: 350-356, 1999; J. Exp. Med. 186: 1481-1486, 1997; Nat. Med. 2: 1122-1128, 1996).
  • a further increase in the effectivity of genetic immunization is due to the inherent immune-enhancing properties of the DNA itself, i.e., the presence of CpG-motifs in the plasmid backbone, which activate both dendritic cells (J. Immunol. 161 : 3042-3049, 1998) and B-cells (Nature 374: 546-549, 1995).
  • Genetic immunization and production of high affinity monoclonal antibodies has been successful in mice (Biotechniques 16: 616-620, 1994; J. Biotechnol. 51 : 191-194, 1996; Hybridoma 17: 569-576, 1998; J. Virol. 72: 4541-4545, 1998;. J. Immunol. 160: 1458-1465, 1998; J.
  • Fully human antibodies are antibody molecules in which the entire sequence of both the light chain and the heavy chain, including the CDRs, arise from human genes. Such antibodies are termed "human antibodies", or "fully human antibodies” herein. Human monoclonal antibodies can be prepared by methods known in the art, see Immunol Today 4: 72, 1983; In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R.
  • techniques can be adapted for the production of single-chain antibodies specific to an antigenic protein of the invention (see e.g., U.S. Patent No. 4,946,778).
  • methods can be adapted for the construction of F ab expression libraries (see e.g., Science 246: 1275-1281 , 1989) to allow rapid and effective identification of monoclonal F a fragments with the desired specificity for a protein or derivatives, fragments, analogs or homologs thereof.
  • Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for an antigenic protein of the invention.
  • the second binding target is any other antigen, and advantageously is a cell-surface protein or receptor or receptor subunit.
  • bispecific antibodies are known in the art, see Nature, 305:537-539, 1983 and 05/be purified by affinity chromatography steps, also see WO 93/08829; EMBO J., 10:3655-3659, 1991.
  • immunotoxins can be constructed using a disulfide exchange reaction or by forming a thioether bond.
  • suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980. It can be desirable to modify the antibody of the invention with respect to effector function, see for example, J. Exp Med., 176: 1191-1195, 1992; J. Immunol., 148: 2918-2922, 1992;Cancer Research, 53: 2560-2565, 1993; Anti-Cancer Drug Design, 3: 219-230, 1989.
  • the invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope ⁇ i.e., a radioconjugate).
  • a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope ⁇ i.e., a radioconjugate).
  • Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes.
  • diphtheria A chain nonbinding active fragments of diphtheria toxin
  • exotoxin A chain from Pseudomonas aeruginosa
  • ricin A chain abrin A chain
  • modeccin A chain alpha-
  • radionuclides are available for the production of radioconjugated antibodies. Examples include 12 Bi, 131 l, 131 ln, 90 Y, and 186 Re. Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutareldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate),
  • a ricin immunotoxin can be prepared as described Science, 238: 1098, 1987.
  • Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See W094/11026.
  • the antibody in another embodiment, can be conjugated to a "receptor" (such streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand” (e.g., avidin) that is in turn conjugated to a cytotoxic agent.
  • a "ligand” e.g., avidin
  • the antibodies disclosed herein can also be formulated as immunoliposomes prepared by methods known in the art, such as described in PNAS USA, 82: 3688, 1985; PNAS USA, 77: 4030, 1980; and U.S. Pat. Nos. 4,485,045; 4,544,545; and 5,013,556; J. Biol. Chem., 257: 286-288, 1982; J. National Cancer Inst, 81 (19): 1484, 1989.
  • methods for the screening of antibodies that possess the desired specificity include, but are not limited to, enzyme linked immunosorbent assay (ELISA) and other immunologically mediated techniques known within the art.
  • ELISA enzyme linked immunosorbent assay
  • selection of antibodies that are specific to a particular domain of CG55069 protein is facilitated by generation of hybridomas that bind to the fragment of CG55069 protein possessing such a domain.
  • antibodies that are specific for a desired domain within CG55069 protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.
  • Antibodies directed against CG55069 protein of the invention may be used in methods known within the art relating to the localization and/or quantitation of CG55069 protein (e.g., for use in measuring levels of CG55069 protein within appropriate physiological samples, for use in diagnostic methods, for use in imaging the protein, and the like).
  • antibodies specific to CG55069 protein, or derivative, fragment, analog or homolog thereof, that contain the antibody derived antigen binding domain are utilized as pharmacologically active compounds (referred to hereinafter as "Therapeutics").
  • An antibody specific for CG55069 protein of the invention can be used to isolate CG55069 polypeptide by standard techniques, such as immunoaffinity, chromatography or immunoprecipitation.
  • An antibody to CG55069 polypeptide can facilitate the purification of a natural CG55069 antigen from cells, or of a recombinantly produced CG55069 antigen expressed in host cells.
  • an anti-CG55069 antibody can be used to detect the antigenic CG55069 protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the antigenic CG55069 protein.
  • Antibodies directed against a CG55069 protein can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling ⁇ i.e., physically linking) the antibody to a detectable substance.
  • detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials.
  • suitable enzymes include horseradish peroxidase, alkaline phosphatase, ⁇ -galactosidase, or acetylcholinesterase;
  • suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin;
  • suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin;
  • an example of a luminescent material includes luminol;
  • examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include 125 l, 131 l, 35 S or 3 H.
  • Antibodies of the invention may be used as therapeutic agents. Such agents will generally be employed to treat or prevent a disease or pathology in a subject.
  • An antibody preparation preferably one having high specificity and high affinity for its target antigen, is administered to the subject and will generally have an effect due to its binding with the target. Such an effect may be one of two kinds, depending on the specific nature of the interaction between the given antibody molecule and the target antigen in question. In the first instance, administration of the antibody may abrogate or inhibit the binding of the target with an endogenous ligand to which it naturally binds.
  • the antibody binds to the target and masks a binding site of the naturally occurring ligand, wherein the ligand serves as an effector molecule.
  • the receptor mediates a signal transduction pathway for which ligand is responsible.
  • the effect may be one in which the antibody elicits a physiological result by virtue of binding to an effector binding site on the target molecule.
  • the target a receptor having an endogenous ligand which may be absent or defective in the disease or pathology, binds the antibody as a surrogate effector ligand, initiating a receptor-based signal transduction event by the receptor.
  • a therapeutically effective amount of an antibody of the invention relates generally to the amount needed to achieve a therapeutic objective.
  • this may be a binding interaction between the antibody and its target antigen that, in certain cases, interferes with the functioning of the target, and in other cases, promotes a physiological response.
  • the amount required to be administered will furthermore depend on the binding affinity of the antibody for its specific antigen, and will also depend on the rate at which an administered antibody is depleted from the free volume other subject to which it is administered.
  • Common ranges for therapeutically effective dosing of an antibody or antibody fragment of the invention may be, by way of nonlimiting example, from about 0.1 mg/kg body weight to about 50 mg/kg body weight.
  • Common dosing frequencies may range, for example, from twice daily to once a week.
  • Antibodies specifically binding a protein of the invention, as well as other molecules identified by the screening assays disclosed herein, can be administered for the treatment of various disorders in the form of pharmaceutical compositions.
  • Principles and considerations involved in preparing such compositions, as well as guidance in the choice of components are provided, for example, in Remington: The Science And Practice Of Pharmacy 19th ed. (Alfonso R. Gennaro, et al., editors) Mack Pub. Co., Easton, Pa. : 1995; Drug Absorption Enhancement : Concepts, Possibilities, Limitations, And Trends, Harwood Academic Publishers, Langhorne, Pa., 1994; and Peptide And Protein Drug Delivery (Advances In Parenteral Sciences, Vol. 4), 1991 , M.
  • antigenic protein is intracellular and whole antibodies are used as inhibitors, internalizing antibodies are preferred.
  • liposomes can also be used to deliver the antibody, or an antibody fragment, into cells. Where antibody fragments are used, the smallest inhibitory fragment that specifically binds to the binding domain of the target protein is preferred.
  • peptide molecules can be designed that retain the ability to bind the target protein sequence. Such peptides can be synthesized chemically and/or produced by recombinant DNA technology. See, e.g., PNAS USA, 90: 7889-7893, 1993.
  • the formulation herein can also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other.
  • the composition can comprise an agent that enhances its function, such as, for example, a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent.
  • cytotoxic agent such as, for example, a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent.
  • Such molecules are suitably present in combination in amounts that are effective for the purpose intended.
  • the active ingredients can also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles, and nanocapsules) or in macroemulsions.
  • colloidal drug delivery systems for example, liposomes, albumin microspheres, microemulsions, nano-particles, and nanocapsules
  • macroemulsions for example, liposomes, albumin microspheres, microemulsions, nano-particles, and nanocapsules
  • the formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes. Sustained-release preparations can be prepared.
  • sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsules.
  • sustained-release matrices include polyesters, hydrogels (for example, poly (2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No.
  • copolymers of L-glutamic acid and y ethyl-L-glutamate non-degradable ethylene-vinyl acetate
  • degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT TM (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate)
  • poly-D-(-)-3-hydroxybutyric acid While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods.
  • An agent for detecting an analyte protein is for example, an antibody capable of binding to an analyte protein, preferably an antibody with a detectable label.
  • Antibodies can be polyclonal, or more preferably, monoclonal.
  • An intact antibody, or a fragment thereof e.g., F ab or F (ab)2
  • the term "labeled", with regard to the probe or antibody is intended to encompass direct labeling of the probe or antibody by coupling ⁇ i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled.
  • Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin.
  • the ter "biological sample” is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. Included within the usage of the term "biological sample”, therefore, is blood and a fraction or component of blood including blood serum, blood plasma, or lymph. That is, the detection method of the invention can be used to detect an analyte mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo.
  • in vitro techniques for detection of an analyte mRNA include Northern hybridizations and in situ hybridizations.
  • In vitro techniques for detection of an analyte protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence.
  • In vitro techniques for detection of an analyte genomic DNA include Southern hybridizations. Procedures for conducting immunoassays are described, for example in "ELISA: Theory and Practice: Methods in Molecular Biology", Vol. 42, J. R. Crowther (Ed.) Human Press, Totowa, NJ, 1995; "Immunoassay", E. Diamandis and T.
  • analyte protein in vivo techniques for detection of an analyte protein include introducing into a subject a labeled anti-an analyte protein antibody.
  • the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.
  • Sequences described herein were generally derived by laboratory cloning of cDNA fragments covering the full length and/or part of the DNA sequence of the invention, and/or by in silico prediction of the full length and/or part of the DNA sequence of the invention from public human sequence databases.
  • CG55069-16 SEQ ID NO: 4 2376 aa MW at 265358.9kD Protein Sequence jLQQTENDTFENGKVNSDTMPTNTVSLPSGDNGKLGGFTQENNTE SGELDIGRRAIQEIPPGIFWRSQ ILFIDQPQFLKFNISLQKDALIGVYGRKGLPPSHTQYDFVELLDGSRLIAREQRSLLETERAGRQARSV 'SLHEAGFIQYLDSGIWHLAFYNDGKNAEQVSFNTIVIESVVECPRNCHGlSrGECVSGTCHCFPGFLGPD CSRAACPVLCSGNGQYSKGRCLCFSGWKGTECDVPTTQCIDPQCGGRGICIMGSCACNSGYKGESCEE
  • Example 3 Quantitative expression analysis of clones in various cells and tissues The quantitative expression of various NOV genes was assessed using microtiter plates containing RNA samples from a variety of normal and pathology-derived cells, cell lines and tissues using real time quantitative PCR (RTQ-PCR) performed on an Applied Biosystems (Foster City, CA) ABI PRISM® 7700 or an ABI PRISM® 7900 HT Sequence Detection System.
  • RTQ-PCR real time quantitative PCR
  • RNA integrity of all samples was determined by visual assessment of agarose gel electropherograms using 28S and 18S ribosomal RNA staining intensity ratio as a guide (2:1 to 2.5:1 28s:18s) and the absence of low molecular weight RNAs (degradation products).
  • Control samples to detect genomic DNA contamination included RTQ-PCR reactions run in the absence of reverse transcriptase using probe and primer sets designed to amplify across the span of a single exon.
  • RNA samples were normalized in reference to nucleic acids encoding constitutively expressed genes (i.e., ⁇ -actin and GAPDH).
  • RNA samples were converted to single strand cDNA (sscDNA) using Superscript II (Invitrogen Corporation, Carlsbad, CA, Catalog No. 18064-147) and random hexamers according to the manufacturer's instructions. Reactions containing up to 10 ⁇ g of total RNA in a volume of 20 ⁇ l or were scaled up to contain 50 ⁇ g of total RNA in a volume of 100 ⁇ l and were incubated for 60 minutes at 42°C. sscDNA samples were then normalized in reference to nucleic acids as described above.
  • Probes and primers were designed according to Applied Biosystems Primer Express Software package (version I for Apple Computer's Macintosh Power PC) or a similar algorithm using the target sequence as input. Default reaction condition settings and the following parameters were set before selecting primers: 250 nM primer concentration; 58°-60° C primer melting temperature (Tm) range; 59° C primer optimal Tm; 2° C maximum primer difference (if probe does not have 5' G, probe Tm must be 10° C greater than primer Tm; and 75 bp to 100 bp amplicon size. The selected probes and primers were synthesized by Synthegen (Houston, TX).
  • Probes were double purified by HPLC to remove uncoupled dye and evaluated by mass spectroscopy to verify coupling of reporter and quencher dyes to the 5' and 3' ends of the probe, respectively. Their final concentrations were: 900 nM forward and reverse primers, and 200nM probe.
  • Results were recorded as CT values (cycle at which a given sample crosses a threshold level of fluorescence) and plotted using a log scale, with the difference in RNA concentration between a given sample and the sample with the lowest CT value being represented as 2 to the power of delta CT.
  • the percent relative expression was the reciprocal of the RNA difference multiplied by 100.
  • CT values below 28 indicate high expression, between 28 and 32 indicate moderate expression, between 32 and 35 indicate low expression and above 35 reflect levels of expression that were too low to be measured reliably.
  • Normalized sscDNA was analyzed by RTQ-PCR using 1X TaqMan® Universal Master mix (Applied Biosystems; catalog No. 4324020), following the manufacturer's instructions. PCR amplification and analysis were done as described above.
  • Panels 1.3D included 2 control wells (genomic DNA control and chemistry control) and 94 wells of cDNA samples from cultured cell lines and primary normal tissues.
  • Cell lines were derived from carcinomas (ca) including: lung, small cell (s cell var), non small cell (non-s or non-sm); breast; melanoma; colon; prostate; glioma (glio), astrocytoma (astro) and neuroblastoma (neuro); squamous cell (squam); ovarian; liver; renal; gastric and pancreatic from the American Type
  • Panels 2D included 2 control wells and 94 wells containing RNA or cDNA from human surgical specimens procured through the National Cancer Institute's Cooperative Human Tissue Network (CHTN) or the National Disease Research Initiative (NDRI), Ardais (Lexington, MA) or Clinomics BioSciences (Frederick, MD). Tissues included human malignancies and in some cases matched adjacent normal tissue (NAT). Information regarding histopathological assessment of tumor differentiation grade as well as the clinical stage of the patient from which samples were obtained was generally available. Normal tissue RNA and cDNA samples were purchased from various commercial sources such as Clontech (Palo Alto, CA), Research Genetics and Invitrogen (Carlsbad, CA). Panels 4D
  • Panels 4D included 2 control wells and 94 test samples of RNA (Panel 4R) or cDNA (Panels 4D and 4.1 D) from human cell lines or tissues related to inflammatory conditions.
  • Controls included total RNA from normal tissues such as colon, lung (Stratagene, La Jolla, CA), thymus and kidney (Clontech, Palo Alto, CA).
  • Total RNA from cirrhotic and lupus kidney was obtained from BioChain Institute, Inc., (Hayward, CA). Crohn's intestinal and ulcerative colitis samples were obtained from the National Disease Research Interchange (NDRI, Philadelphia, PA).
  • cytokines IL-1 beta -1-5 ng/ml, TNF alpha -5-10 ng/ml, IFN gamma -20-50 ng/ml, IL-4 -5-10 ng/ml, IL.-9 -5-10 ng/ml, IL-135-10 ng/ml
  • Starved endothelial cells were cultured in the basal media (Clonetics, Walkersville, MD) with 0.1 % serum.
  • LAK cells were prepared from blood donations using Ficoll.
  • LAK cells were cultured in culture media [DMEM, 5% FCS (Hyclone, Logan, UT), 100 mM non essential amino acids (Gibco/Life Technologies, Rockville, MD), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5 x 10 "5 M (Gibco), and 10 mM Hepes (Gibco)] and interleukin 2 for 4-6 days.
  • RNA preparation was activated with 10-20 ng/ml PMA and 1-2 ⁇ g/ml ionomycin, 5-10 ng/ml IL-12, 20-50 ng/ml IFN gamma or 5- 10 ng/ml IL-18 for 6 hours.
  • mononuclear cells were cultured for 4-5 days in culture media with -5 mg/ml PHA (phytohemagglutinin) or PWM (pokeweed mitogen; Sigma- Aldrich Corp., St. Louis, MO). Samples were taken at 24, 48 and 72 hours for RNA preparation.
  • PHA phytohemagglutinin
  • PWM pokeweed mitogen
  • MLR mixed ly phocyte reaction
  • Monocytes were isolated from mononuclear cells using CD14 Miltenyi Beads, +ve VS selection columns and a Vario Magnet (Miltenyi Biotec, Auburn, CA) according to the manufacturer's instructions. Monocytes were differentiated into dendritic cells by culturing in culture media with 50 ng/ml GMCSF and 5 ng/ml IL-4 for 5-7 days. Macrophages were prepared by culturing monocytes for 5-7 days in culture media with -50 ng/ml 10% type AB Human Serum (Life technologies, Rockville, MD) or MCSF (Macrophage colony stimulating factor; R&D, Minneapolis, MN).
  • Monocytes, macrophages and dendritic cells were stimulated for 6 or 12-14 hours with 100 ng/ml lipopolysaccharide (LPS). Dendritic cells were also stimulated with 10 ⁇ g/ml anti-CD40 monoclonal antibody (Pharmingen, San Diego, CA) for 6 or 12-14 hours.
  • LPS lipopolysaccharide
  • CD4+ lymphocytes, CD8+- lymphocytes and NK cells were also isolated from mononuclear cells using CD4, CD8 and CD56 Miltenyi beads, positive VS selection columns and a Vario Magnet (Miltenyi Biotec, Auburn, CA) according to the manufacturer's instructions.
  • CD45+RA and CD45+RO CD4+ lymphocytes were isolated by depleting mononuclear cells of CD8+, CD56+, CD14+ and CD19+ cells using CD8, CD56, CD14 and CD19 Miltenyi beads and positive selection. CD45RO Miltenyi beads were then used to separate the CD45+RO CD4+ lymphocytes from CD45+RA CD4+ lymphocytes.
  • CD45+RA CD4+, CD45+RO CD4 +and CD8+ lymphocytes were cultured in culture media at 10 6 cells/ml in culture plates precoated overnight with 0.5 mg/ml anti-CD28 (Pharmingen, San Diego, CA) and 3 ⁇ g/ml anti-CD3 (OKT3, ATCC) in PBS. After 6 and 24 hours, the cells were harvested for RNA preparation. To prepare chronically activated CD8+ lymphocytes, isolated CD8+ lymphocytes were activated for 4 days on anti-CD28, anti-CD3 coated plates and then harvested and expanded in culture media with IL-2 (1 ng/ml). These CD8+ cells were activated again with plate bound anti-CD3 and anti-CD28 for 4 days and expanded as described above. RNA was isolated 6 and 24 hours after the second activation and after 4 days of the second expansion culture. Isolated NK cells were cultured in culture media with 1 ng/ml IL-2 for 4-6 days before RNA was prepared.
  • B cells were prepared from minced and sieved tonsil tissue (NDRI). Tonsil cells were pelleted and resupended at 10 6 cells/ml in culture media. Cells were activated using 5 ⁇ g/ml PWM (Sigma- Aldrich Corp., St. Louis, MO) or -10 ⁇ g/ml anti-CD40 (Pharmingen, San Diego, CA) and 5-10 ng/ml IL-4. Cells were harvested for RNA preparation after 24, 48 and 72 hours.
  • PWM Sigma- Aldrich Corp., St. Louis, MO
  • -10 ⁇ g/ml anti-CD40 Pharmingen, San Diego, CA
  • 5-10 ng/ml IL-4 Cells were harvested for RNA preparation after 24, 48 and 72 hours.
  • umbilical cord blood CD4+ lymphocytes (Poietic Systems, German Town, MD) were cultured at 10 5 -10 6 cells/ml in culture media with IL-2 (4 ng/ml) in 6-well Falcon plates (precoated overnight with 10 ⁇ g/ml anti-CD28 (Pharmingen) and 2 ⁇ g/ml anti-CD3 (OKT3; ATCC) then washed twice with PBS).
  • Th1 phenotype differentiation To stimulate Th1 phenotype differentiation, IL-12 (5 ng/ml) and anti-IL4 (1 ⁇ g/ml) were used; for Th2 phenotype differentiation, IL-4 (5 ng/ml) and anti-IFN gamma (1 ⁇ g/ml) were used; and for Tr1 phenotype differentiation, IL-10 (5 ng/ml) was used. After 4-5 days, the activated Th1 , Th2 and Tr1 lymphocytes were washed once with DMEM and expanded for 4-7 days in culture media with IL-2 (1 ng/ml).
  • Th1 , Th2 and Tr1 lymphocytes were re-stimulated for 5 days with anti-CD28/CD3 and cytokines as described above with the addition of anti-CD95L (1 ⁇ g/ml) to prevent apoptosis. After 4-5 days, the Th1 , Th2 and Tr1 lymphocytes were washed and expanded in culture media with IL-2 for 4-7 days. Activated Th1 and Th2 lymphocytes were maintained for a maximum of three cycles. RNA was prepared from primary and secondary Th1 , Th2 and Tr1 after 6 and 24 hours following the second and third activations with plate-bound anti- CD3 and anti-CD28 mAbs and 4 days into the second and third expansion cultures.
  • Leukocyte cells lines Ramos, EOL-1 , KU-812 were obtained from the ATCC. EOL-1 cells were further differentiated by culturing in culture media at 5 x10 5 cells/ l with 0.1 mM dbcAMP for 8 days, changing the media every 3 days and adjusting the cell concentration to 5 x10 5 cells/ml.
  • RNA was prepared from resting cells or cells activated with PMA ("10 ng/ml) and ionomycin (1 ⁇ g/rnl) for 6 and 14 hours.
  • RNA was prepared from resting CCD 1106 keratinocyte cell line (ATCC) or from cells activated with -5 ng/ml TNF alpha and 1 ng/rnl IL-1 beta.
  • RNA was prepared from resting NCI-H292, airway epithelial tumor cell line (ATCC) or from cells activated for 6 and 14 hours in culture media with 5 ng/ml IL-4, 5 ng/ml IL-9, 5 ng/ml IL-13, and 25 ng/ml IFN gamma.
  • ATCC airway epithelial tumor cell line
  • RNA was prepared by lysing approximately 10 7 cells/ml using Trizol (Gibco BRL) then adding 1/10 volume of bromochloropropane (Molecular Research Corporation, Cincinnati, OH), vortexing, incubating for 10 minutes at room temperature and then spinning at 14,000 rpm in a Sorvali SS34 rotor. The aqueous phase was placed in a 15 ml Falcon Tube and an equal volume of isopropanol was added and left at -20° C overnight. The precipitated RNA was spun down at 9,000 rpm for 15 min and washed in 70% ethanol.
  • RNAse-free water with 35 ml buffer (Promega, Madison, WI) 5 ⁇ l DTT, 7 ⁇ I RNAsin and 8 ⁇ l DNAse and incubated at 37° C for 30 minutes to remove contaminating genomic DNA, extracted once with phenol chloroform and re-precipitated with 1/10 volume of 3 M sodium acetate and 2 volumes of 10O% ethanol.
  • the RNA was spun down, placed in RNAse free water and stored at -80° C.
  • Thyroid 2.0 0.8 0.6 0.2 Salivary gland 0.2 0.1 0.0 0.1 jPituitary gland 3.5 0.6 0.8 I 0.1 i Brain (fetal) 8.7 0.6 2.3 1.1
  • ICD8 lymphocyte act I o.o 0.0 0.0 o.o
  • ⁇ Secondary CD8 lymphocyte act 0.0 0.0 0.0 o.o
  • the expression of the CG53018-01 gene was assessed in three independent runs in panel 2D using two different probe/p> rimer sets.
  • the highest expression of this gene is generally associated with kidney cancers. Of particular note is the consistent absence of expression in normal kidney tissue adjacent to malignant kidney.
  • the expression of this gene could be used to distinguish the above listed malignant tissue from other tissues in the panel.
  • the expression of this gene could be used to distinguish malignant kidney tissue from normal kidney.
  • therapeutic modulation of this gene through the use of small molecule drugs, antibodies or protein therapeutics is of benefit in the treatment of kidney cancer, ovarian cancer, bladder cancer or lung cancer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des nouveaux polynucléotides Ten-M3 codant de nouveaux polypeptides et des anticorps qui se lient immunospécifiquement au polypeptide, ainsi que des dérivés, des variantes, des mutants ou de fragments de ces nouveaux polypeptides, polynucléotides ou anticorps spécifiques des polypeptides. L'invention concerne également des vecteurs, des cellules hôtes, des anticorps, et des procédés de recombinaison permettant de produire les polypeptides et polynucléotides, ainsi que des procédés pour les utiliser. L'invention concerne en outre des procédés thérapeutiques, de diagnostic et de recherche pour le diagnostic, le traitement et la prévention de troubles impliquant l'un au moins de ces nouveaux acides nucléiques et protéines humains.
PCT/US2005/010680 2004-03-30 2005-03-30 Polypeptides et polynucleotides ten-m3, et procedes d'utilisation correspondants WO2005094365A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55797804P 2004-03-30 2004-03-30
US60/557,978 2004-03-30

Publications (2)

Publication Number Publication Date
WO2005094365A2 true WO2005094365A2 (fr) 2005-10-13
WO2005094365A3 WO2005094365A3 (fr) 2006-04-13

Family

ID=35064326

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/010680 WO2005094365A2 (fr) 2004-03-30 2005-03-30 Polypeptides et polynucleotides ten-m3, et procedes d'utilisation correspondants

Country Status (1)

Country Link
WO (1) WO2005094365A2 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005500815A (ja) * 2000-12-29 2005-01-13 キュラジェン コーポレイション タンパク質およびそれをコードする核酸

Also Published As

Publication number Publication date
WO2005094365A3 (fr) 2006-04-13

Similar Documents

Publication Publication Date Title
CN100447244C (zh) Baff受体(bcma),一种免疫调节剂
AU784338B2 (en) Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
EP0871702B1 (fr) Cytokine designee par lerk-7
US20080241835A1 (en) Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
JP2007222180A (ja) 腫瘍性細胞成長阻害のための組成物及び方法
JP2002533134A (ja) ペプチドグリカン認識タンパク質
JPH09509826A (ja) 活性化ｃｄ４▲上＋▼ｔ細胞の表層上のレセプターに対するリガンド（ａｃｔ−４−ｌ）
JP2004519215A (ja) クローディンポリペプチド
US7176180B2 (en) Type 2 cytokine receptor and nucleic acids encoding same
JP2002543784A (ja) 新規なチンパンジーエリスロポエチン（ｃｈｅｐｏ）ポリペプチドおよびこれをコードする核酸
US20040029216A1 (en) Proteins, polynucleotides encoding them and methods of using the same
JPH10505750A (ja) 粘着および軸索の成長を刺激するサイトタクチン誘導体並びにその製造および使用方法
US20020010137A1 (en) Methods and compositions for inhibiting neoplastic cell growth
JP4280444B2 (ja) 腫瘍性細胞成長阻害のための組成物及び方法
JP2009219492A (ja) Ｇｄｎｆｒと配列類似性を有する新規ポリペプチド及びこれをコードする核酸
WO2006041205A1 (fr) Promoteur d'angiogenese
US20050244868A1 (en) Ten-M3 polypeptides and polynucleotides and their methods of use
WO2005094365A2 (fr) Polypeptides et polynucleotides ten-m3, et procedes d'utilisation correspondants
EA027940B1 (ru) Пептиды, обладающие способностью индуцировать цитотоксические т-лимфоциты, и их применение
EP1263955A2 (fr) Nouveaux polypeptides et acides nucleiques les codant
WO2005051995A2 (fr) Nouvelle proteine de type recepteur specifique au produit d'extremite d'une glycosylation avancee et acides nucleiques codant cette proteine
CN101371923B (zh) Baff受体(bcma),一种免疫调节剂
US20060141565A1 (en) Novel fibroblast growth factor and uses thereof
EP1484338B1 (fr) Méthode et composition pour l'inhibition de la croissance des cellules néoplastiques
US7214497B2 (en) Viral encoded semaphorin protein receptor DNA and polypeptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase